In the future, medical representatives will continue to be under pressure, where is the way out?

Under the superposition of factors such as national centralized procurement, the new version of the medical insurance catalog, medical reforms to correct wind, and the epidemic, medical representatives have not had an easy life in recent years
.
Among them, especially under the normalization of centralized procurement, the life of drug generation is becoming more and more difficult
.
Some analysts pointed out that although in the long run, the accelerated promotion of centralized procurement policies will benefit the benign and high-quality development of the pharmaceutical industry, cutting off bribery channels from the source and playing a certain role in anti-corruption of pharmaceuticals
.
But in the short term, pharmaceutical companies and pharmaceutical representatives are being forced to accelerate their transformation and upgrading
.
In the future, medical representatives will continue to be under pressure, where is the way out? (Image source: Pharmaceutical Network) The author understands that under the current industry background, pharmaceutical representatives are already facing an increasingly difficult market development situation while continuing to respond to the wave of layoffs by pharmaceutical companies
.
It is reported that since 2021, a large number of multinational pharmaceutical companies and local pharmaceutical companies, including Pfizer and Yiling Pharmaceutical, have successively reported that they have laid off their sales teams
.
So, in the context of the continuous deepening of medical reform and the normalization of centralized procurement, how should these medical representatives find new ways in the future? In this regard, the industry believes that the current pharmaceutical industry is undergoing major changes, and the professional environment of pharmaceutical representatives has also undergone fundamental changes
.
Therefore, there are only two ways for medical representatives, either to change careers or to transform
.
In fact, in the context of medical reform, overlapping layoffs, transformation, and salary cuts, countless medical representatives have begun to look for new outlets
.
Among them, many pharmaceutical agents have begun to plan their transformation.
The main transformation directions include doctor brokers, medical device sales representatives, and the establishment of medical device operating companies
.
Judging from the current direction of the transformation of pharmaceutical representatives, the industry believes that in the future, pharmaceutical representatives will be divided into three parts.
First, pharmaceutical representatives with high academic qualifications and strong professional capabilities will develop in the direction of medical academics and pharmaceutical exchanges; secondly, they will have strong sales capabilities.
Pharmacy representatives will develop in the direction of pharmacies, private hospitals, and clinics in addition to public hospitals; again, medical representatives will also transform their work at the business level, such as channel docking, delivery and payment, etc.
, in fact, they also need medicines.
Take it on your behalf
.
From the above comprehensive point of view, the analysis believes that medical representatives will not disappear in the future, and with China’s emphasis on innovative drugs and the acceleration of the speed and scope of the launch of innovative drugs, the role and value of pharmaceutical representatives will become greater and greater.

.
This can be clearly seen from the fact that pharmaceutical companies still have a strong demand for medical representatives under multiple pressures
.
It is understood that the demand for the position of medical representative in the recruitment announcements of many pharmaceutical companies is still very strong
.
For example, the Cinda Bio&Blood team recently recruited medical representatives to be responsible for the listing of Dabova (rituximab) and third-generation Tki (oribatinib) at the end of the year
.
Xi'an Janssen Pharmaceutical Co.
, Ltd.
is also recruiting senior pharmaceutical representatives to be responsible for new urology products with good market prospects
.
In addition, Sino-US East China, CSPC, Enhai Baijin, and Abbott (Shanghai) Trading Co.
, Ltd.
have also released relevant recruitment information
.
Just be aware that, judging from the recruitment announcements of major pharmaceutical companies, as pharmaceutical companies have become more focused on the delivery of product information and increased sensitivity to the market, the requirements for pharmaceutical representatives have also been further improved
.
Especially in order to cooperate with the launch of innovative drugs, pharmaceutical companies will need more professional and capable medical representatives to share professional disease knowledge, drug use information, and patient management knowledge with doctors
.
In this context, the industry predicts that only when medical representatives develop in a more orderly, compliant, and professional direction, can they have a better future
.